Phase 1b/2, Open Label, study of Alcalabrutinib alone or in combination with Rituximab in subjects with Indolent B-Cell, Non-Hodgkins Lymphoma (MZL)

Type of Cancer
Lymphoma

Sponsor
Acerta

Protocol Number
ACE-LY-003 Part 2(MZL) Amendment 4

To Learn More Call
(201)-510-0950